

# pNiFty2-IFA-SEAP

Inducible reporter plasmid selectable with Zeocin™

Catalog code: pnf2-ifasp

## For research use only

Version 20L03-MM

## PRODUCT INFORMATION

### Contents:

- 20 µg of pNiFty2-IFA-SEAP provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

### Storage and stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20 °C.
- Resuspended DNA should be stored at -20 °C and is stable for up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

### Quality control:

- Plasmid construct has been confirmed by restriction analysis and full-length ORF sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

## GENERAL PRODUCT USE

Interferons are key modulators of the immune response. Their pleiotropic activities are mediated by the induction of many IFN-stimulated genes (ISGs). To help study the transcriptional regulation and signal transduction of type I IFNs, InvivoGen provides several reporter systems, called pNiFty2, based on the inducible expression of the secreted embryonic alkaline phosphatase (SEAP) gene. The SEAP gene is cloned under the control of three different promoters that are activated by various transcription factors, such as IRF3, IRF5, IRF7 and NF-κB. pNiFty2-IFA-SEAP features the mouse IFN $\alpha$  promoter.

## PLASMID FEATURES

- **mIFN $\alpha$  prom** is the mouse interferon alpha 4 minimal promoter<sup>1</sup>. Transcription of mIFN $\alpha$ 4 is mediated by a virus responsive element (VRE-A4) located in the promoter. VRE-A4 contains four cooperating DNA modules that bind to IRF3 and IRF7<sup>2</sup>. Co-expression of IFN $\alpha$ -SEAP with constitutively activated IRF3 (saIRF3) or IRF7 (saIRF7) in HEK293 cells led to a strong increase in SEAP expression.
- **5U-140 is a synthetic 5'UTR**
- **5U-140** is a synthetic 5'UTR containing an intron.
- **SEAP** is a secreted form of human embryonic alkaline phosphatase. Unlike endogenous alkaline phosphatases, SEAP is extremely heat stable and resistant to the inhibitor L-homoarginine. It catalyses the hydrolysis of pNitrophenyl phosphate (pNpp) producing a yellow end product. SEAP expression can be readily quantified by collecting samples of culture medium and measuring the hydrolysis of pNpp with a spectrophotometer at 405 nm.
- **SV40 pAn**: The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA.
- **hEF1/HTLV prom** is a composite promoter comprising the Elongation Factor-1 $\alpha$  (EF-1 $\alpha$ ) core promoter<sup>3</sup> and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat<sup>4</sup>. The EF-1 $\alpha$  promoter exhibits a strong activity and yields long lasting expression of a transgene in vivo. The R-U5' has been coupled to the EF-1 $\alpha$  core promoter to enhance stability of RNA.

- **EM7** is a bacterial promoter that enables the constitutive expression of the Zeocin™ antibiotic resistance gene in *E. coli*.

**• Zeo:** Resistance to the antibiotic Zeocin™ is conferred by the *Sh ble* gene from *Streptallocteichus hindustanus*. The *Sh ble* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.

**• BGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription<sup>5</sup>.

**• pMB1 Ori** is a minimal *E. coli* origin of replication with the same activity as the longer Ori.

**1. Braganca J. et al., 1997.** Synergism between multiple virus-induced factor-binding elements involved in the differential expression of interferon A genes. *J Biol Chem.* 272(35):22154-62. **2. Morin P. et al., 2002.** Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription. *J Mol Biol.* 316(5):1009-22. **3. Kim DW. et al., 1990.** Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. *Gene.* 91(2): 217-23. **4. Takebe Y. et al., 1988.** SR alphapromoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol.* 8(1):466-72. **5. Yu J & Russell JE., 2001.** Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H<sub>2</sub>O. Store resuspended plasmid at -20 °C.

### Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

### Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

## TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong : +852 3-622-34-80

E-mail: info@invivogen.com



125

Sdal (6)

1 CCTGCAGGGGCAGGTTCTGCATCCCTGGACCCCTGCTGGTTCAGTTACCCCCACACTTACTTTTGACAGAAATTTATGAAATAGTATAAATA

101 AAACAAAAGGTGAAAATAATTACAAAACCTTAAACAGTCATAGGGGAATTGTGTTGAGTAGTGTGAGTTTACACAGAGACTGT

201 ATATCTGTGGAGTAGTGTAACTGACAATTAAAGTGTAACTTAAGAGAACCTGGAGAGTAGCTTCTGAGGGCAGCAGTGAACACTGAAACATGAT

301 TGAACCCACATTCCCAGGGGGGGGGGGAGGGAGAACAAATCCAGACACAAGCAGAGAGTGAAGTAAGAAAGTAAAGAGAATTGAAAGCAAG

HindIII (486)

401 GGGAGGGTATTCCGAAGGAGAACCTGTATTGCTTCTATTAAAGAGAGATGTACACAGCAGGCTCTCAGAGAACCTGTAGGAGAAGCTCTGCCTCT

501 CCTCTGTGAGTTGtaagtactgactgtctatgcggaaagggtggcaggagatgggcagtgaggaaaatggcactatgaaccTGAGC

XbaI (613)

601 CCTAGGAATGCATCAGAattgtactaacctttcttccttcgtacag6TTGGTGTACAGTAGCTTACCATGGTTCTGGGCCCTGCATG

701 CTGCTGCTGCTGCTGCTGGCCCTGAGGCTACAGCTCCCTGGCATCCAGTTGAGGAGGAACCCGAGTCTGGAACCGCGAGGCCG

801 AGGCCCCGGTGGCCCAAGAAGCTGCAGCCTGCAGACAGCAGGCCAAGAACCTCATCTCTGGGATGGGATGGGGTGTACGGTACAGC

41▶ IuAl aLeuGl yAl aAl aLysLysLeuGl nProAl aGl nThr Al aAl aLysAsnLeuI iLei ePheLeuGl yAl metGl yVal Ser Thr Val Thr Al

BamHI (906)

901 TGCCAGGATCTAAAGGGCAGAAGAAGGACAAACTGGGCTGAGATAACCCCTGGCTATGGACCGCTTCCATATGTTCTGCTCAAGACATACAAT

74▶ aAl aArg IeLeuLysGl yGl nLysLysAspLysLeuGl yProGl IiLePleuAl aMetAspArgPheProTyrVal Al aLeuSer LysThr TyrAsn

1001 GTAGACAAACATGGCCAGCAGTGGGACACAGGCCACGGCTACCTGCGGGCTAAGGCAACTTCCAGACGATTGCTTGAAGTGCAGCGCCG

108▶ ValAspLysHisI ProAspSer Gl yAl aThrAl aThrIaTyrLeuLysGl yVal LysLysAsnPheGl nThr IeGl yLeuSer Al aAl aAl aArgP

1101 TAAACAGTGGCACACGACCGGGCACAGGCTATCTCGTGTAGATCCTGGCAGAACAGCAGGCCAAGAACCTCATCTCTGGGATGGTAACCACACAGG

141▶ heAsnGl nCysAsnThr Thr ArgGl yAsnGl vAl iLeSer Val MetAsnArgAl aLysLysAl aGl yLysSer Val Gl yVal Val Thr Thr ArgVa

1201 GCAGCACGCTGCCAGCCGACCTAGGCCACAGGTGAACCGCACTGGTACTCGGACGCCAGTGCCCTGCCGCCGCCAGGAGGGTGCAG

174▶ IGl nHi sAl aSer ProAl aGl yThr TyrAl aHi sThr Val AsnArgTrpYerSAl aProAl aSer Al aArgGl nGl yLysGl n

1301 GACATCGCTACCGCAGCTCATCTAACACATGGACATGGTGTGATCTGGGTTGGAGGCGAAAGTACATGTTGCATGGGAACCCAGACCTGAGTAC

208▶ AspI iLeAl aThr Gl nLeuI LeSer AsnMetAspI iLeAspVal iLeLeuGl yGl yArgLysTyrMetPheArgMetGl yThr ProAspProGl uTyp

1401 CAGATGACTACAGCCAAGTGGGACAGGCTGGACGGGAAGAATCTGGTCAGGAATGGCTGGCGAAGCGCAGGGTGCCTGATGGTGTGGAACCCAC

241▶ roAspAspTyrSer Gl nGl yGl yThr ArgLeuAspGl yLysLysLeuVal Gl nGl uTrpLeuAl aLysArgGl nGl yAl aArgTyrVal TrpAsnArgTh

1501 TGAGCTCATCGAGCTTCCGGACCGCTGTGACCCATCTCATGGCTCTTGGAGCCTGGAGACATGAAATCAGAGATCCACCGAGACTCCACACTG

274▶ rGl nLeuMetGl nAl aSer LeuAspProSer Val Thr Hi LeuMetGl yLeuPheGl uProGl yAspMetLysTyrGl iLeHi sArgAspSer Thr Leu

1601 GACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGCGCTGAGCAGGAACCCCGCGCGCTTCTCTCTCTGGAGGGTGTGCGATCGACAC

308▶ AspProSer LeuMetGl uMetThr Gl uAl aAl aLeuArgLeuSer ArgAsnProArgGl yPhePheLeuPheVal Gl uGl yGl yArgI iLeAspHsG

1701 GTCATACGAAAGCAGGGCTTACGGGCACTGACTGAGACGATCATGTTGACGCCATTGAGGGCCAGCTCACCAGCGAGGAGACACGCT

341▶ IyHi sHi sGl uSer ArgAl aTyrArgAl aLeuThr Gl uThr I iLeMetPheAspAspAl iLeGl uArgAl aGl yGl nLeuThr Ser Gl uGl uAspThr Le

BbsI (1834)

1801 GAGCCTGTCACTGCCGACCACTCCACGCTCTCTCTGGAGGCTACCCCTGCGAGGGAGCTCATCTCGGGCTGGCCCTGCAAGGCCGGAC

374▶ uSer LeuVal ThriAl aAspHi sSer Hi sVal PheSer PheGl yGl yTyrProLeuArgGl ySer Ser I iLePheGl yLeuAl aProGl yLysAl aArgAsp

StuI (1907)

1901 AGGAAGGCTCACCGCTCTCTATACGGAAACGGTCCAGGCTATGTGCTCAAGGACGGCCGGCCGGATGTTACCGAGAGCAGGGAGCCG

408▶ ArgLysAl aTyrThr Val LeuLeuTyrGl yAsnGl yProGl yTyrVal LeuLysAspGl yAl aArgProAspVal Thr Gl uSer Gl ySer ProG

2001 AGTATCGGCAGCTGCACTGCTGGACGAAGAGACCCAGCAGGCCAGGGACGTTGCGCGCCGGCAGGGCACCTGGTCAAGG

441▶ IuTyArgGl nGl nSer Al aAl aProLeuAspGl uGl uThr Hi LeuAspVal Al aValAl aValAl aArgGl yProGl nAl aHi sLeuVal Hi sGl

2101 CGTCAGGAGCACCTTCATAGCGCAGCTGGCCCTGCTGGAGGCTACACCGCCCTGGAGGGCCACCCGGCACCACCG

474▶ yVal Gl nGl uGl nThr Phell eAl aHi sVaMetAl aPheAl aAl aCysLeuGl uProTyrThr Al aCysAspLeuAl aProProAl aGl yThr Thr Asp

NheI (2244)

2201 GCCCGCACCCGGGGCGGTCCGGTCAAGCGTCTGGATTGAAGCTAGCTGGCAGACATGATAAGATACTTGTAGTTGGACAAACCAACTAGA

508▶ Al aAl aHi sProGl yArgSer ArgSer LysArgLeuAsp\*\*\*

HpaI (2384)

2301 ATGCACTGAAAAAAATGCTTATTGTGAAATTGTGATCTTGTAACTTATAAGCTCAATAAACAGTTAACACAATTGCA

EcoRI (2478)

2401 TTCTTTATGTTCAAGGTTCAAGGGGAGGTGGAGGTTTTAAAGCAAGTAAACCTCTACAAATGTTGATGGAATTCTAAACATACAGCATGCA

2501 AAACTTAACCTCAAATCAAGCTACTTGAATCTTCTGAGGGATGAATAAGGCATAGGCATCAGGGCTGTTGCCAATGTGCTTGTGTTG

2601 CAGCCTCACCTCTTCACTGGAGTTAAGATATAGTGTATTCTCAAGGTTGAAGTCTTCTTATGTTAAATGCACTGACTCC

SwI (2734)

2701 ATTCCCTTTAGTAAATATTCAAGAAATAATTAAATACATCATTGCAATGAAATAATGTTTATTAGGCAGATCCAGATGCTCAAGGCC

2801 ATAATATCCCCAGTTAGTGTGGACTTAGGAAACAAAGAACCTTAATAGAAATTGGACAGCAAGAAAGCAGCTCTAGCTTATCCTCAGCTCTG

2901 CTCCCTGCCAACAAAGTGCACGCAGTGGCCGGGGTGCAGGGCAACTCCGCCACGGCTGCTGCCGATCTGGTCACTGGCGCCGGAG

122▶ Gl uGl uAl aVal PheHi sVal CysAsnGl yAl aProAspArgLeuAl aPheGl uArgGl yTrpProGl nGl yI iLeGl uThr MetAl aProGl ySer A

3001 GCGTCCGGAAAGTCTGGACACGACCTCCGACCATCTGGCGTACAGCTCGCCAGGGCCACCCACCCAGGGTGTGCGCACAC

88▶ IaAspArgPheAsnThr Ser Val Val Gl uSer TrpGl uAl aTyrLeuGl uAspLeuGl yArgVal TrpVal TrpAl aLeuThr AsnAspProVal Val Gl

SgrAI (3147)

3101 GGTCTGGACCGCGCTGATGAACAGGGTCACGTCCTGGACCAACGGCGAACAGTCGCTCTCCACAGAAGTCCGGAGAACCGAGCCGGTGGCCA

55▶ nAspGl nVal Al aSer I iLePheLeuThr Val AspAspArgVal Val Gl yAl aPheAspAspGl uVal PheAspArgSer PheGl yLeuArgAspThr Trp

3201 GAACTCGACCGCTCCGGCGACGCTCGCGCGCGTGGACACCGGAACGGCACTGGTCAACTGGCCATGATGGCCCTCTATAGTGTAGCTATTACTAT

22▶ PheGl uVal Al aGl yAl aVal AspArgAl aThr LeuVal ProVal Al aSer Thr LeuLysAl aMet

AseI (3322)

3301 GCCGATATACTATGCCGATGATTAATTGCAACTACTGTTGAGGCAGCTTCAGCTTGATCTGTAACGGCAGAACAGAAAAGCAAAGAC

3401 GTAGAGTTGAGCAAGCAGGGTCAAGGAGAGCGCTGAGTCTAGGTAGGCTCAAGGGAGCGCCGACAAAGGCCGGTCTGACCTGAGC

3501 TTTAAACTACCTAGACGGCGGACCGCAGTCAGGAGGCACCACAGGGGGAGGCCAGAACCGCACTCAACCGCGTGGATGGCGCCTCAGGTAGGGC

HindIII (3635)  
3601 **GGCGGGCGGTGAAGGAGAGATCGGAGCCCCCTGAAGCTTCAGCTGTGTTCTGGCGAAACCCGTTGC**AAAAAGAACGTTCACGGC~~GACTACTGCACT~~

---

AgI (3791)  
3701 **TATATACGGTTCTCCCCACCCCTCGGAAAAGGCCGAGCCAGTACACGACATC**ACTTCCCAGTTACCCGC~~CCAC~~TTCTAGGCACCGTTCAA

---

SpeI (3860) SdaI (3875) PacI (3882)  
3801 **TTGCCGACCCCTCCCCA**CTTCGGGACTGTGGCGATGTGCGCTTGCC~~ACTGACT~~AGTGGCCCTGCAGGTTAATTAAAGAACATGTGAGCAA

---

3901 **AGGCCAGCAAAGGCCAGAACGTA**AAAAGGCCGCGTGTGGCTTCCATAGGCTGCCCTGACGAGCATC  
4001 CAGAGGTGGCGAACCCGACAGGACTATAAAGATAACCAGCGTTCCCTGGAAGCTCCCTCGTGCCTCCCTGTTCCGACCC~~TGCGCTACCG~~GAT

---

4101 ACCTGTCCGCCCTTCTCCCGGAAGCGTGGCCTTCTCATAGCTACGCTGAGGTATCTCAGTTGGTAGGTGCTCCAGCTCAAGCTGGCTG

---

4201 TGTGACGAACCCCCGTT~~CAGCCGACCGCTGC~~CCCTTATCCGTA~~ACTATCGTCTGAGTCCA~~ACCCGGTAAGACACGACTTATGCCACTGGCAGCA

---

4301 GCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTGAAGTGGCCTA~~ACTACGGCTACACTAGAAGAACAGT~~TATTG

---

4401 GTATCTCGCTCTGCTGAAGCCAGTTACCTCGGAAAAGAGTTGGTAGCTCTTGATCCGGAAACAAACCACCGCTGGTAGCGTGGTTTTTGTGTTG

---

4501 CAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATC~~CTTGATCTTCTACGGG~~TCTGACGCTCAGTGGAACGAAACTCACGTTAAGGG

---

PacI (4622) SwaI (4630) NotI (4638)  
4601 ATTTGGTCATGGCTAGTTAATTAA~~CATTTAA~~ATCAGCGGCCG~~C~~AATAAAATATCTTATTTCATTACATCTGTTGGTTTTTGTA~~CGTA~~

---

4701 ACTAACATACGCTCTCCATCAAACAAACGAAACAAA~~AAACTAGC~~AAATAGGCTGCCCCAGTGC~~AGTGCAGGTGCC~~AGAACATTCTATCGA

---

XbaI (4815) Acc65I (4829)  
SgfI (4812) EcoRI (4822)  
4801 AGGATCTCGATCGCTCGAGTGAATTCTGGTA